Bile salts and cholestasis

Digestive and Liver Disease

Volumn 42, Issue 6, 2010, Pages 409-418

  Maillette de Buy Wenniger, Lucas ^a   Beuers, Ulrich ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Bile acids; Chenodeoxycholate; Primary biliary cirrhosis; Primary sclerosing cholangitis; Ursodeoxycholate

Indexed keywords

6 ETHYLCHENODEOXYCHOLIC ACID; BILE SALT; CHENODEOXYCHOLIC ACID; CHOLIC ACID; NORURSODEOXYCHOLIC ACID; PLACEBO; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE; BILE ACID;

ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; BILE FLOW; BIOCHEMISTRY; BIOSYNTHESIS; CANCER RISK; CHEMICAL ANALYSIS; CHOLESTASIS; CLINICAL TRIAL; CYSTIC FIBROSIS ASSOCIATED LIVER DISEASE; DETOXIFICATION; DIGESTION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; GLUCOSE METABOLISM; HUMAN; IMMUNITY; INBORN ERROR OF BILE SALT METABOLISM; INBORN ERROR OF METABOLISM; INTESTINE FLORA; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MEMBRANE DAMAGE; MITOCHONDRION; MOLECULAR EVOLUTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; ANIMAL; BILE DUCT; DISEASE COURSE; INTESTINE ABSORPTION; LIVER CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BILE ACIDS AND SALTS; BILE DUCTS; BIOLOGICAL TRANSPORT, ACTIVE; CHOLESTASIS; DISEASE PROGRESSION; HEPATOCYTES; HUMANS; INTESTINAL ABSORPTION;

EID: 77952744201     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.03.015     Document Type: Short Survey

References (190)

1. Hofmann A.F., Eckmann L. How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci USA 2006, 103:4333-4334.
2. Begley M., Gahan C.G., Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005, 29:625-651.
3. Hofmann A.F., Hagey L.R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008, 65:2461-2483.
4. Hylemon P.B., Zhou H., Pandak W.M., et al. Bile acids as regulatory molecules. J Lipid Res 2009, 50:1509-1520.
5. Zollner G., Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009, 156:7-27.
6. Schmucker D.L., Ohta M., Kanai S., et al. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990, 12:1216-1221.
7. Hofmann A.F., Roda A. Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem. J Lipid Res 1984, 25:1477-1489.
8. Griffiths W.J., Sjovall J. Bile acids: analysis in biological fluids and tissues. J Lipid Res 2009.
9. Hofmann A.F., Hagey L.R., Krasowski M.D. Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res 2009.
10. Monte M.J., Marin J.J., Antelo A., Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol 2009, 15:804-816.
11. Perez M.J., Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol 2009, 15:1677-1689.
12. Roda A., Grigolo B., Minutello A., et al. Physicochemical and biological properties of natural and synthetic C-22 and C-23 hydroxylated bile acids. J Lipid Res 1990, 31:289-298.
13. Hofmann A.F., Mysels K.J. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res 1992, 33:617-626.
14. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:318-328.
15. Hagey L.R., Crombie D.L., Espinosa E., et al. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J Lipid Res 1993, 34:1911-1917.
16. Sola S., Garshelis D.L., Amaral J.D., et al. Plasma levels of ursodeoxycholic acid in black bears, Ursus americanus: seasonal changes. Comp Biochem Physiol C Toxicol Pharmacol 2006, 143:204-208.
17. Poupon R.E., Chretien Y., Poupon R., Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993, 17:599-604.
18. Reddy S., Sanders T.A., Owen R.W., Thompson M.H. Faecal pH, bile acid and sterol concentrations in premenopausal Indian and white vegetarians compared with white omnivores. Br J Nutr 1998, 79:495-500.
19. van Faassen A., Hazen M.J., van den Brandt P.A., et al. Bile acids and pH values in total feces and in fecal water from habitually omnivorous and vegetarian subjects. Am J Clin Nutr 1993, 58:917-922.
20. Bisschop P.H., Bandsma R.H., Stellaard F., et al. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am J Clin Nutr 2004, 79:570-576.
21. Asakura H., Suzuki K., Kitahora T., Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis?. J Gastroenterol Hepatol 2008, 23:1794-1801.
22. Meier P.J., Stieger B. Bile salt transporters. Annu Rev Physiol 2002, 64:635-661.
23. Strautnieks S.S., Bull L.N., Knisely A.S., et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998, 20:233-238.
24. Duarte I.F., Legido-Quigley C., Parker D.A., et al. Identification of metabolites in human hepatic bile using 800MHz 1H NMR spectroscopy. HPLC-NMR/MS and UPLC-MS. Mol Biosyst 2009, 5:180-190.
25. Chari R.S., Schutz S.M., Haebig J.E., et al. Adenosine nucleotides in bile. Am J Physiol 1996, 270:G246-G252.
26. Chen B., Dong J.Q., Chen Y.J., et al. Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary Pancreat Dis Int 2007, 6:402-406.
27. Farina A., Dumonceau J.M., Frossard J.L., et al. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res 2009, 8:159-169.
28. Kristiansen T.Z., Bunkenborg J., Gronborg M., et al. A proteomic analysis of human bile. Mol Cell Proteomics 2004, 3:715-728.
29. Glickerman D.J., Kim M.H., Malik R., Lee S.P. The gallbladder also secretes. Dig Dis Sci 1997, 42:489-491.
30. von Ritter C., Eder M.I., Stieber P., et al. Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res 1997, 17:2931-2934.
31. Hofmann A.F. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci 2009, 14:2584-2598.
32. Hruz P., Zimmermann C., Gutmann H., et al. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 2006, 55:395-402.
33. Ballatori N., Fang F., Christian W.V., et al. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am J Physiol Gastrointest Liver Physiol 2008, 295:G179-G186.
34. Ballatori N., Li N., Fang F., Boyer J.L., et al. OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Front Biosci 2009, 14:2829-2844.
35. Ma K., Xiao R., Tseng H.T., et al. Circadian dysregulation disrupts bile acid homeostasis. PLoS One 2009, 4:e6843.
36. +-dependent bile acid transporter is associated with cholehepatic shunting in rats. Hepatology 2005, 41:1037-1045.
37. Xia X., Francis H., Glaser S., et al. Bile acid interactions with cholangiocytes. World J Gastroenterol 2006, 12:3553-3563.
38. Fickert P., Wagner M., Marschall H.U., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
39. Glaser S.S., Alpini G. Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis. Hepatology 2009, 49:1795-1797.
40. Shindo K., Machida M., Fukumura M., Koide K., Yamazaki R. Omeprazole induces altered bile acid metabolism. Gut 1998, 42:266-271.
41. Beuers U., Fischer S., Spengler U., Paumgartner G. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. J Hepatol 1991, 13:97-103.
42. Toda T., Ohi K., Kudo T., et al. Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora. Drug Metab Pharmacokinet 2009, 24:201-208.
43. Lepercq P., Hermier D., David O., et al. Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br J Nutr 2005, 93:457-469.
44. Handschin C., Meyer U.A. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 2005, 433:387-396.
45. Tietz P.S., Marinelli R.A., Chen X.M., et al. Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes. J Biol Chem 2003, 278:20413-20419.
46. Lam I.P., Lee L.T., Choi H.S., et al. Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). Am J Physiol Gastrointest Liver Physiol 2009, 297:G90-G97.
47. Pande C., Kumar A., Sarin S.K. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther 2009, 29:1273-1281.
48. Gunnarsdottir S.A., Sadik R., Shev S., et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003, 98:1362-1370.
49. Slocum M.M., Sittig K.M., Specian R.D., Deitch E.A. Absence of intestinal bile promotes bacterial translocation. Am Surg 1992, 58:305-310.
50. Kurdi P., Kawanishi K., Mizutani K., Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol 2006, 188:1979-1986.
51. Inagaki T., Moschetta A., Lee Y.K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006, 103:3920-3925.
52. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009, 136:1435-1443.
53. Stange E.F. For bugs in bile: the times they are a-changin. Gastroenterology 2009, 136:1164-1167.
54. Ding J.W., Andersson R., Soltesz V., et al. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. Eur Surg Res 1993, 25:11-19.
55. Beuers U. Effects of bile acids on hepatocellular signaling and secretion. Yale J Biol Med 1997, 70:341-346.
56. Anwer M.S. Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology 2004, 39:581-590.
57. Zollner G., Marschall H.U., Wagner M., Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006, 3:231-251.
58. Anwer M.S., Engelking L.R., Nolan K., et al. Hepatotoxic bile acids increase cytosolic Ca++ activity of isolated rat hepatocytes. Hepatology 1988, 8:887-891.
59. Beuers U., Nathanson M.H., Boyer J.L. Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes. Gastroenterology 1993, 104:604-612.
60. Beuers U., Throckmorton D.C., Anderson M.S., et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996, 110:1553-1563.
61. Bouscarel B., Kroll S.D., Fromm H. Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Gastroenterology 1999, 117:433-452.
62. Rao Y.P., Stravitz R.T., Vlahcevic Z.R., et al. Activation of protein kinase C alpha and delta by bile acids: correlation with bile acid structure and diacylglycerol formation. J Lipid Res 1997, 38:2446-2454.
63. Beuers U., Nathanson M.H., Isales C.M., Boyer J.L. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis. J Clin Invest 1993, 92:2984-2993.
64. Misra S., Ujhazy P., Gatmaitan Z., et al. The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver. J Biol Chem 1998, 273:26638-26644.
65. Misra S., Ujhazy P., Varticovski L., Arias I.M. Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles. Proc Natl Acad Sci USA 1999, 96:5814-5819.
66. Beuers U., Denk G.U., Soroka C.J., et al. Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. J Biol Chem 2003, 278:17810-17818.
67. Haussinger D., Kurz A.K., Wettstein M., et al. Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis. Gastroenterology 2003, 124:1476-1487.
68. Dent P., Fang Y., Gupta S., et al. Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology 2005, 42:1291-1299.
69. Nguyen A., Bouscarel B. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal 2008, 20:2180-2197.
70. Lefebvre P., Cariou B., Lien F., et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009, 89:147-191.
71. Zhang Y., Lee F.Y., Barrera G., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006, 103:1006-1011.
72. Houten S.M., Watanabe M., Auwerx J. Endocrine functions of bile acids. EMBO J 2006, 25:1419-1425.
73. Keitel V., Kubitz R., Haussinger D. Endocrine and paracrine role of bile acids. World J Gastroenterol 2008, 14:5620-5629.
74. Watanabe M., Houten S.M., Mataki C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
75. Ikemoto S., Takahashi M., Tsunoda N., et al. Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am J Physiol 1997, 273:E37-45.
76. Makishima M., Lu T.T., Xie W., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
77. Ishizawa M., Matsunawa M., Adachi R., et al. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res 2008, 49:763-772.
78. Kawamata Y., Fujii R., Hosoya M., et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003, 278:9435-9440.
79. Yamazaki K., Gleich G.J., Kita H. Bile acids induce eosinophil degranulation by two different mechanisms. Hepatology 2001, 33:582-590.
80. Bergamini A., Dini L., Baiocchi L., et al. Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells. Hepatology 1997, 25:927-933.
81. Oumi M., Yamamoto T. A scanning electron microscope study on the effects of different bile salts on the epithelial lining of jejunal mucosa. Med Electron Microsc 2000, 33:11-15.
82. Benedetti A., Alvaro D., Bassotti C., et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 1997, 26:9-21.
83. Hofmann A.F. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999, 159:2647-2658.
84. Palmeira C.M., Rolo A.P. Mitochondrially-mediated toxicity of bile acids. Toxicology 2004, 203:1-15.
85. Sokol R.J., McKim J.M., Goff M.C., et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 1998, 114:164-174.
86. Schubert R., Schmidt K.H. Structural changes in vesicle membranes and mixed micelles of various lipid compositions after binding of different bile salts. Biochemistry 1988, 27:8787-8794.
87. Lemasters J.J. The mitochondrial permeability transition: from biochemical curiosity to pathophysiological mechanism. Gastroenterology 1998, 115:783-786.
88. Lemasters J.J., Nieminen A.L., Qian T., et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998, 1366:177-196.
89. Lemasters J.J., Theruvath T.P., Zhong Z., Nieminen A.L. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta 2009, 1787:1395-1401.
90. Sokol R.J., Dahl R., Devereaux M.W., et al. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J Pediatr Gastroenterol Nutr 2005, 41:235-243.
91. Rolo A.P., Palmeira C.M., Wallace K.B. Mitochondrially mediated synergistic cell killing by bile acids. Biochim Biophys Acta 2003, 1637:127-132.
92. Sokol R.J., Winklhofer-Roob B.M., Devereaux M.W., McKim J.M. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 1995, 109:1249-1256.
93. Gumpricht E., Devereaux M.W., Dahl R., et al. Resistance of young rat hepatic mitochondria to bile acid-induced permeability transition: potential role of alpha-tocopherol. Pediatr Res 2008, 64:498-504.
94. Yerushalmi B., Dahl R., Devereaux M.W., et al. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 2001, 33:616-626.
95. Prince M.I., Mitchison H.C., Ashley D., et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther 2003, 17:137-143.
96. Reinehr R., Graf D., Haussinger D. Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Gastroenterology 2003, 125:839-853.
97. Reinehr R., Becker S., Keitel V., et al. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005, 129:2009-2031.
98. Rust C., Wild N., Bernt C., et al. Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem 2009, 284:2908-2916.
99. Schoemaker M.H., Conde de la Rosa L., Buist-Homan M., et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 2004, 39:1563-1573.
100. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008, 7:1013-1030.
101. Kaplowitz N., Than T.A., Shinohara M., Ji C. Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007, 27:367-377.
102. Iizaka T., Tsuji M., Oyamada H., et al. Interaction between caspase-8 activation and endoplasmic reticulum stress in glycochenodeoxycholic acid-induced apoptotic HepG2 cells. Toxicology 2007, 241:146-156.
103. Hitomi J., Katayama T., Eguchi Y., et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol 2004, 165:347-356.
104. Bochkis I.M., Rubins N.E., White P., et al. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat Med 2008, 14:828-836.
105. Kitani K., Ohta M., Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol 1985, 248:G407-G417.
106. Wimmer R., Hohenester S., Pusl T., et al. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut 2008, 57:1448-1454.
107. 2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol 2006, 168:398-409.
108. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525-531.
109. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001, 35:134-146.
110. Beuers U., Boyer J.L., Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998, 28:1449-1453.
111. Dombrowski F., Stieger B., Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 2006, 86:166-174.
112. Beuers U., Bilzer M., Chittattu A., et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001, 33:1206-1216.
113. Fiorotto R., Spirli C., Fabris L., et al. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007, 133:1603-1613.
114. Minagawa N., Nagata J., Shibao K., et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007, 133:1592-1602.
115. Nathanson M.H., Burgstahler A.D., Masyuk A., Larusso N.F. Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem J 2001, 358:1-5.
116. Rodrigues C.M., Fan G., Ma X., et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998, 101:2790-2799.
117. Serviddio G., Pereda J., Pallardo F.V., et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004, 39:711-720.
118. Rodrigues C.M., Steer C.J. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. Expert Opin Investig Drugs 2001, 10:1243-1253.
119. Mitsuyoshi H., Nakashima T., Sumida Y., et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999, 263:537-542.
120. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
121. Poupon R.E., Balkau B., Eschwege E., Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991, 324:1548-1554.
122. Heathcote E.J., Cauch-Dudek K., Walker V., et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149-1156.
123. Lindor K.D., Dickson E.R., Baldus W.P., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284-1290.
124. Combes B., Carithers R.L., Maddrey W.C., et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759-766.
125. Pares A., Caballeria L., Rodes J., et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000, 32:561-566.
126. Corpechot C., Carrat F., Bonnand A.M., et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196-1199.
127. Poupon R.E., Lindor K.D., Cauch-Dudek K., Dickson E.R., Poupon R., Heathcote E.J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-890.
128. Goulis J., Leandro G., Burroughs A. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999, 354:1053-1060.
129. Gong Y., Huang Z., Christensen E., Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007, 102:1799-1807.
130. Shi J., Wu C., Lin Y., et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006, 101:1529-1538.
131. Lindor K.D., Poupon R., Heathcote E.J., Therneau T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000, 355:657-658.
132. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128:297-303.
133. Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006, 130:715-720.
134. Corpechot C., Abenavoli L., Rabahi N., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008, 48:871-877.
135. Kuiper E.M., Hansen B.E., de Vries R.A., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136:1281-1287.
136. Chazouilleres O., Poupon R., Capron J.P., et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990, 11:120-123.
137. O'Brien C.B., Senior J.R., Arora-Mirchandani R., et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991, 14:838-847.
138. Beuers U., Spengler U., Kruis W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16:707-714.
139. Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand J Gastroenterol Suppl 1994, 204:59-61.
140. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
141. Rost D., Rudolph G., Kloeters-Plachky P., Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004, 40:693-698.
142. Mitchell S.A., Bansi D.S., Hunt N., et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
143. Harnois D.M., Angulo P., Jorgensen R.A., et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558-1562.
144. Cullen S.N., Rust C., Fleming K., et al. High dose ursodeoxycholic acid for the treatment of primary sclerosig cholangitis is safe and effective. J Hepatol 2008, 48:792-800.
145. Olsson R., Boberg K.M., de Muckadell O.S., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-1472.
146. Lindor K.D., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
147. Lindor K.D., Enders F.B., Schmoll J.A., et al. Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid for primary sclerosing cholangitis. Hepatology 2008, 48:378A.
148. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
149. Tung B.Y., Emond M.J., Haggitt R.C., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
150. Wolf J.M., Rybicki L.A., Lashner B.A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783-788.
151. Pardi D.S., Loftus E.V., Kremers W.K., et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
152. Rudolph G., Kloeters-Plachky P., Rost D., Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007, 19:487-491.
153. Lazaridis K.N., Gores G.J. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006, 26:42-51.
154. Brandsaeter B., Isoniemi H., Broome U., et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815-822.
155. Palma J., Reyes H., Ribalta J., et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997, 27:1022-1028.
156. Williamson C., Hems L.M., Goulis D.G., et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 2004, 111:676-681.
157. Roncaglia N., Locatelli A., Arreghini A., et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004, 111:17-21.
158. Glantz A., Marschall H.U., Lammert F., Mattsson L.A. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005, 42:1399-1405.
159. Kondrackiene J., Beuers U., Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005, 129:894-901.
160. Binder T., Salaj P., Zima T., Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006, 34:383-391.
161. Glantz A., Reilly S.J., Benthin L., et al. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008, 47:544-551.
162. Colombo C., Battezzati P.M., Podda M., et al. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996, 23:1484-1490.
163. van de Meeberg P.C., Houwen R.H., Sinaasappel M., et al. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997, 32:369-373.
164. Lindblad A., Glaumann H., Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27:166-174.
165. Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009, 4:1.
166. Jacquemin E., De Vree J.M., Cresteil D., et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001, 120:1448-1458.
167. Nathwani R.A., Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006, 10:207-217. vii.
168. Essell J.H., Schroeder M.T., Harman G.S., et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:975-981.
169. Ohashi K., Tanabe J., Watanabe R., et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000, 64:32-38.
170. Ruutu T., Eriksson B., Remes K., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
171. Tay J., Tinmouth A., Fergusson D., et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:206-217.
172. DeLeve L.D., Valla D.C., Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009, 49:1729-1764.
173. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
174. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
175. Pelletier G., Roulot D., Davion T., et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 2003, 37:887-892.
176. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
177. Mancinelli R., Onori P., Gaudio E., et al. Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression. Exp Biol Med (Maywood) 2009, 234:462-474.
178. Ueno Y., Francis H., Glaser S., et al. Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway. Exp Biol Med (Maywood) 2007, 232:942-949.
179. Marzioni M., Ueno Y., Glaser S., et al. Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. Liver Int 2007, 27:558-568.
180. Sundaram S.S., Bove K.E., Lovell M.A., Sokol R.J. Mechanisms of disease: inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol 2008, 5:456-468.
181. Oude Elferink R.P., Paulusma C.C., Groen A.K. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006, 130:908-925.
182. Heubi J.E., Setchell K.D., Bove K.E. Inborn errors of bile acid metabolism. Semin Liver Dis 2007, 27:282-294.
183. Gonzales E., Gerhardt M.F., Fabre M., et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. Gastroenterology 2009, 137. 1310-20 e1-3.
184. Halilbasic E., Fiorotto R., Fickert P., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009, 49:1972-1981.
185. Hofmann A.F., Zakko S.F., Lira M., et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 2005, 42:1391-1398.
186. Hofmann A.F. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 2009, 49:1403-1418.
187. Yoon Y.B., Hagey L.R., Hofmann A.F., et al. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 1986, 90:837-852.
188. Cipriani S., Mencarelli A., Palladino G., Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2009.
189. Fiorucci S., Clerici C., Antonelli E., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005, 313:604-612.
190. Wang X.X., Jiang T., Shen Y., et al. Farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 2009.